New types of CAR-T cells with its CAR construct of BCR light chain neoepitope composed of a characteristic point mutation (IGLV3-21(R110)) are able to selectively target poor-risk subset of chronic lymphocytic leukaemia (CLL), exert epitope-selective cytolysis effects, and effectively protect normal human B cells [55]. Here, BCR is linked to B-cell chronic lymphocytic leukemia.